Brief: CanSino Biologics Says DTcP-Hib-MCV4 Combined Vaccine Obtains Clinical Trial Approval By NMPA China
24/02/2025 10:20
Feb 24 (Reuters) - CanSino Biologics Inc 688185.SS :
* DTCP-HIB-MCV4 COMBINED VACCINE OBTAINS CLINICAL TRIAL
APPROVAL
BY NMPA CHINA
Further company coverage: 688185.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025